What is it about?
Esophageal squamous cell carcinoma (ESCC) is a leading cause of cancer death worldwide. Despite significant progress in diagnosing and treating ESCC, the survival rate remains low, with less than 20% of patients surviving after five years. Cancer-associated fibroblasts (CAFs) are known to play a critical role in ESCC tumor metabolism, angiogenesis, immune evasion, and metastasis by secreting factors. Therefore, targeting the CAFs-secreted protein may be a promising therapeutic approach. In this study, we aim to explore the therapeutic potential of targeting CAFs-secreted proteins and enhance our understanding of their function and effects in treating ESCC.
Featured Image
Photo by Ani Kolleshi on Unsplash
Why is it important?
Our study revealed that CAFs in ESCC specifically secrete MFGE8, a protein that plays a critical role in CAF-mediated processes such as vascularization, tumor proliferation, drug resistance, and metastasis. By targeting CAFs secreted MFGE8 or its receptor, we observed significant inhibitory effects on the growth and metastasis of ESCC. These findings provide a potential therapeutic approach for treating ESCC.
Read the Original
This page is a summary of: Targeting MFGE8 secreted by cancer-associated fibroblasts blocks angiogenesis and metastasis in esophageal squamous cell carcinoma, Proceedings of the National Academy of Sciences, October 2023, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2307914120.
You can read the full text:
Contributors
The following have contributed to this page
